Fundraising FoxAeovian Pharmaceuticals
Berkeley, US · Founded 2012 · Delaware corporation · 8 known investors
Find your way into Aeovian Pharmaceuticals
Sign up to see every warm intro you have to Aeovian Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Aeovian Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing selective small molecule inhibitors to treat rare genetic and age-related diseases caused by dysregulated cellular metabolism. The company's lead candidate, AV078, is a CNS-penetrant mTORC1 inhibitor in development for tuberous sclerosis complex refractory epilepsy.
Founders & leadership
DR
Davis RymanChief Medical OfficerBoard-certified neurologist and geneticist with over 10 years of experience in pharmaceutical and biotechnology development and academic research focused on neurological and genetic disorders. Ryman has led clinical development programs for multiple neurological indications including spinal muscular atrophy, Alzheimer's disease, and Parkinson's disease, with contributions to FDA-approved therapies including ZOLGENSMA and DUOPA.
IM
Ian MasseyNamed on SEC filing
ST
Stelios TzannisNamed on SEC filing
BZ
Ben ZadikNamed on SEC filing
DL
David LoweNamed on SEC filing
JP
James PeyerNamed on SEC filing
Board
RG
YB
TK
Themasap KhanBoard director
Investors · 8
FJ Labslisted by FJ LabsNew York · $100K – $3M
How we know: FJ Labs's portfolio page · the VCSheet dataset · Not right? Tell us
Luma Grouplisted by Luma GroupNew York
How we know: Luma Group's portfolio page · a partner's Signal profile · Not right? Tell us
Sofinnova Ventureslisted by Sofinnova VenturesMenlo Park · $100K – $15Mvia Lars Ekman · board
How we know: Sofinnova Ventures's portfolio page · board seat on SEC Form D · the VCSheet dataset · Not right? Tell us
venBio Partnerslisted by venBio PartnersSan Franciscovia Richard Gaster · board
How we know: a partner's Signal profile · board seat on SEC Form D · the VCSheet dataset · Not right? Tell us
Apollo Health VenturesreportedBerlin
How we know: a partner's Signal profile · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$125M disclosed across 4 rounds · 2017–2025
▶$55MraisedDec 2025 · 13 investors · PharmaceuticalsRule 506(b)
▶$55MraisedDec 2025 · 13 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- John KincaidExecutive Officer
- Youssef BennaniDirector
- Themasap KhanDirector
- Nils ReggeDirector
- Davis RymanExecutive Officer
- William GreeneDirector
- Micah ZajicExecutive Officer
- Lars EkmanDirector
- Justin GoverDirector
- Allison J. HulmeExecutive Officer, Director
- Richard GasterDirector
- Offering amount
- $55M
- Amount sold
- $55M
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$50.4MraisedMay 2024 · 5 investors · PharmaceuticalsRule 506(b)
▶$50.4MraisedMay 2024 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Davis C. RymanExecutive Officer
- Nils ReggeDirector
- Matthew J. PlunkettExecutive Officer
- William GreeneDirector
- Allison J. HulmeExecutive Officer, Director
- John F. KincaidExecutive Officer
- Richard GasterDirector
- Lars EkmDirector
- Offering amount
- $50.4M
- Amount sold
- $50.4M
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$18.8MraisedOct 2019 · 5 investors · PharmaceuticalsRule 506(b)
▶$18.8MraisedOct 2019 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Stelios TzannisExecutive Officer, Director
- Jens EcksteinDirector
- Ben ZadikExecutive Officer
- Michael PowellDirector
- Richard GasterDirector
- Offering amount
- $48.8M
- Amount sold
- $18.8M
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$785.7KraisedJun 2017 · 4 investors · PharmaceuticalsRule 506(b)
▶$785.7KraisedJun 2017 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Ian MasseyExecutive Officer
- Stelios TzannisExecutive Officer, Director
- Ben ZadikExecutive Officer
- David LoweDirector
- James PeyerDirector
- Offering amount
- $3.8M
- Amount sold
- $785.7K
- First sale
- Jun 2017
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
ElevianElevian is a biotechnology company developing rGDF11, a recombinant protein therapy shown in preclinical animal models to promote recovery of motor function after ischemic and hemorrhagic stroke by stimulating new blood vessel formation, neurogenesis, and reducing inflammation. The protein has also shown regenerative effects in preclinical models of aging-related cardiovascular, neurological, metabolic, pulmonary, renal, and skeletal muscle conditions.
Actio Biosciences, Inc.Actio is a precision medicine company that translates genetic insights into new therapeutics, developing drugs that target the genes underlying both rare diseases and more prevalent conditions. It focuses on identifying dysregulated gene activity and designing therapies to restore balance and address the root causes of disease.
IQVIAIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
AzevanAzevan Pharmaceuticals is a clinical-stage biopharmaceutical company developing orally bioavailable V1a receptor antagonists targeting vasopressin biology for neuropsychiatric, neurodegenerative, neurodevelopmental, and brain injury conditions. The company's lead candidate SRX246 has shown efficacy in reducing pathological aggression in Huntington's Disease and Intermittent Explosive Disorder.
Attovia TherapeuticsAttovia is a biotechnology company focused on drug development and clinical strategy, aiming to bring treatments to patients where none exist and create next-generation therapeutic options. Its team includes a leadership team, board of directors, and scientific advisors experienced in drug development and company building.
Companies working in the same space as Aeovian Pharmaceuticals.
In the news
Frequently asked questions
- What does Aeovian Pharmaceuticals do?
- Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing selective small molecule inhibitors to treat rare genetic and age-related diseases caused by dysregulated cellular metabolism. The company's lead candidate, AV078, is a CNS-penetrant mTORC1 inhibitor in development for tuberous sclerosis complex refractory epilepsy.
- Who are Aeovian Pharmaceuticals's investors?
- Aeovian Pharmaceuticals's investors include CoastCap, CTI Life Sciences Fund L.P., FJ Labs, Luma Group, Sofinnova Ventures, venBio Partners, Apollo Health Ventures, venBio Global Strategic.
- How much funding has Aeovian Pharmaceuticals raised?
- Aeovian Pharmaceuticals has disclosed $125M raised across 4 rounds.
- Where is Aeovian Pharmaceuticals headquartered?
- Aeovian Pharmaceuticals is headquartered in Berkeley, US.